TNGX FY 2023 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$37M+46.9% YoY

Gross Profit

$37M100.0% margin

Operating Income

-$114M-312.6% margin

Net Income

-$102M-278.5% margin

EPS (Diluted)

$-1.08

Cash Flow

Operating Cash Flow

-$118M

Free Cash Flow

-$120M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$403M

Total Liabilities

$149M

Stockholders' Equity

$253M

Cash & Equivalents

$66M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37M	$25M	+46.9%
Gross Profit	$37M	$25M	+46.9%
Operating Income	-$114M	-$111M	-2.8%
Net Income	-$102M	-$108M	+5.9%